583 related articles for article (PubMed ID: 12234411)
21. Antitumor treatment efficacy by targeting epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in an orthotopic human glioblastoma model.
Yi D; Hua TX; Lin HY; Kui CL; Ning LX; Wang ZZ
J Neurooncol; 2011 Aug; 104(1):93-101. PubMed ID: 21140283
[TBL] [Abstract][Full Text] [Related]
22. Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model.
Diao Y; Tian XH; Huang YL; Chen LK; Lin XN; Zhuang ZW
J Chemother; 2010 Dec; 22(6):407-12. PubMed ID: 21303749
[TBL] [Abstract][Full Text] [Related]
23. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
[TBL] [Abstract][Full Text] [Related]
25. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability.
Nasu S; Ang KK; Fan Z; Milas L
Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):474-7. PubMed ID: 11567823
[TBL] [Abstract][Full Text] [Related]
26. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.
Prewett M; Rothman M; Waksal H; Feldman M; Bander NH; Hicklin DJ
Clin Cancer Res; 1998 Dec; 4(12):2957-66. PubMed ID: 9865906
[TBL] [Abstract][Full Text] [Related]
27. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.
Schechter NR; Yang DJ; Azhdarinia A; Kohanim S; Wendt R; Oh CS; Hu M; Yu DF; Bryant J; Ang KK; Forster KM; Kim EE; Podoloff DA
Anticancer Drugs; 2003 Jan; 14(1):49-56. PubMed ID: 12544258
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
[TBL] [Abstract][Full Text] [Related]
29. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
Solomon B; Hagekyriakou J; Trivett MK; Stacker SA; McArthur GA; Cullinane C
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):713-23. PubMed ID: 12573759
[TBL] [Abstract][Full Text] [Related]
30. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
[TBL] [Abstract][Full Text] [Related]
31. The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn J
Endocr Relat Cancer; 2001 Mar; 8(1):3-9. PubMed ID: 11350723
[TBL] [Abstract][Full Text] [Related]
32. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.
Prewett M; Rockwell P; Rockwell RF; Giorgio NA; Mendelsohn J; Scher HI; Goldstein NI
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):419-27. PubMed ID: 9041461
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
[TBL] [Abstract][Full Text] [Related]
34. Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma.
Hicks MJ; Chiuchiolo MJ; Ballon D; Dyke JP; Aronowitz E; Funato K; Tabar V; Havlicek D; Fan F; Sondhi D; Kaminsky SM; Crystal RG
PLoS One; 2016; 11(10):e0162978. PubMed ID: 27711187
[TBL] [Abstract][Full Text] [Related]
35. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
[TBL] [Abstract][Full Text] [Related]
36. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
[TBL] [Abstract][Full Text] [Related]
37. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
38. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
39. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
40. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
